This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 55.17% and 5.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 46.30% and 1.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aveanna Healthcare (AVAH) Q1 Earnings Expected to Decline
by Zacks Equity Research
Aveanna (AVAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Elanco Animal Health Incorporated (ELAN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Elanco (ELAN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Elanco (ELAN) stock based on the movements in the options market lately.
Elanco Animal Health Incorporated (ELAN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 46.15% and 0.77%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: DaVita HealthCare (DVA) Q4 Earnings Expected to Decline
by Zacks Equity Research
DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quest Diagnostics (DGX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 4.21% and 3.56%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 25% and 0.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Earnings Season Could Be Great for Elanco (ELAN)
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemed (CHE) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Chemed (CHE) delivered earnings and revenue surprises of 2.82% and 1.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Elanco Animal Health Incorporated (ELAN) Could Beat Earnings Estimates Again
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
McKesson (MCK) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Elanco Animal Health Incorporated (ELAN) Tops Q2 Earnings Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 38.46% and 0.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
AlerisLife (ALR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Five Star (ALR) delivered earnings and revenue surprises of -33.33% and 4.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Aveanna Healthcare (AVAH) Q2 Earnings Expected to Decline
by Zacks Equity Research
Aveanna (AVAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DaVita HealthCare (DVA) Tops Q2 Earnings Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 9% and 0.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amedisys (AMED) Q2 Earnings Beat Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of 19.51% and 4.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Elanco Animal Health Incorporated (ELAN) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 2.86% and 0.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Elanco (ELAN) This Earnings Season?
by Zacks Equity Research
Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.